# Critique: AAA2-02/E01 Final

- Critic: `CRIT-AAA2-02-E01-FINAL-20260913-7F3A`
- Independence: `I1`, fresh-context, read-only
- Scope: `AUD13-16:AAA2-02-E01`, local synthetic slice only
- Decision: `APPROVE`

## Accepted Evidence

- Terminal medication-order states are denied for direct dispensing and reopening.
- Indirect subtractive stock movements reject unknown, foreign, inactive, mismatched and out-of-scope references.
- Manual `DISPENSE` with `referenceId: null` remains supported.
- API role, idempotency, concurrency and no-mutation regressions are covered by the supplied focused and full-suite results.
- Current code, tests, and control boundaries were inspected without observed mutation.

## Limitations

- The approval is only for the local synthetic slice, not the parent `AUD13-16` acceptance or the global Triplo AAA.
- PostgreSQL multi-process medication concurrency was not demonstrated in this slice; the concurrency evidence is HTTP/in-memory.
- Provider, staging, production-like operations, external authority and human approval remain absent.

The critic did not execute commands; command results were independently supplied by the Lead and recorded in `VER-CVG-AAA2-02-002`.
